According to IMARC Group’s latest research report, titled “PEGylated Proteins Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” offers a comprehensive analysis of the industry, which comprises insights on the PEGylated proteins market share. The report also includes competitor and regional analysis, and contemporary advancements in the market. The global PEGylated proteins market size reached US$ 1.16 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.13 Billion by 2028, exhibiting a growth rate (CAGR) of 10.16% during 2023-2028.
PEGylated Proteins Market Outlook:
PEGylated proteins are protein molecules that are conjugated with polyethylene glycol (PEG). Its process involves modifying the surface of proteins in order to extend their half-lives and improve their solubility, stability, and bioavailability. The process covalently attaches one or more PEG molecules to the surface of a protein, resulting in a larger, more hydrophilic molecule. The PEG molecules act as a protective shield, shielding the protein from enzymatic degradation, reducing immunogenicity, and enhancing the pharmacokinetic properties of the protein. Additionally, PEGylated proteins are widely used in biopharmaceuticals due to their improved pharmacokinetic properties and extended half-lives, allowing for longer action duration and improved therapeutic efficacy. PEGylated proteins help in the extension of half-life, increasing stability, solubility, and proteolytic protection, reducing renal excretion, immunogenicity, and toxicity, and enhancing the efficacy of drug delivery. Besides this, PEGylated proteins are non-toxic, water-soluble, hydrophilic, non-antigenic, and non-immunogenic. They are adopted in gene therapy and vaccine delivery as they provide a promising platform for the development of new therapeutic agents to treat a wide range of diseases.
Get Free Sample Copy of Report at – https://www.imarcgroup.com/pegylated-proteins-market/requestsample
PEGylated Proteins Market Trends:
The escalating healthcare expenditure majorly drives the global market. This can be supported by the growing number of chronic illnesses, such as kidney disorders, autoimmune diseases, genetic disorders, hepatitis, and rheumatoid arthritis, among individuals. Along with this, PEGylated proteins are extensively employed to treat inflammation, deliver corrective genes to cells, prevent blood clots, deliver growth hormones, and check the progression of chronic kidney disease is a major driving factor. Additionally, the rising use of PEGylated proteins in cancer treatment to deliver chemotherapy drugs directly to cancer cells and decrease the side effects on healthy cells is impacting the market favorably. Apart from this, continuous advancements in PEGylation technology, such as the development of new PEGylation techniques that can generate smaller and more complex molecules, are creating a positive market outlook. The widespread adoption of PEGylation to improve the stability and half-life of colony-stimulating factors (CSFs), making them more effective as therapeutic agents, is acting as another growth-inducing factor. Furthermore, the rising adoption of protein-based drugs over non-protein-based drugs wherein PEGylation increases the circulation and half-life of the proteins, improving its efficiency, is propelling the market growth. Some of the other factors driving the market include the rising aging population and the implementation of various government initiatives to boost regulatory standards in the pharmaceutical industry.
Key Market Segmentation:
Competitive Landscape with Key Players:
- Abcam plc
- Biomatrik Inc.
- Creative PEGWorks
- Iris Biotech GmbH
- JenKem Technology USA Inc.
- Laysan Bio Inc.
- NOF America Corporation (NOF Corporation)
- Profacgen
- Thermo Fisher Scientific Inc.
Product Insights:
- Consumables
- PEGylation Reagents
- PEGylation Kits
- Services
Protein Type Insights:
- Colony Stimulating Factors
- Interferons
- Erythropoietin
- mAbs
- Recombinant Factor VII
- Others
Application Insights:
- Cancer Treatment
- Hepatitis
- Chronic Kidney Diseases
- Hemophilia
- Multiple Sclerosis
- Gastrointestinal Disorders
- Others
End User Insights:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutes
Breakup by Region:
- North America (United States, Canada)
- Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
- Market Performance
- Market Outlook
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Who we are:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
